- Home
- HMST vs PGEN Comparison
HMST vs PGEN Comparison
Compare HMST & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- PGEN
- Stock Information
- Founded
- HMST 1921
- PGEN 1998
- Country
- HMST United States
- PGEN United States
- Employees
- HMST N/A
- PGEN N/A
- Industry
- HMST Major Banks
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- PGEN Health Care
- Exchange
- HMST Nasdaq
- PGEN Nasdaq
- Market Cap
- HMST 287.6M
- PGEN 292.6M
- IPO Year
- HMST 2012
- PGEN N/A
- Fundamental
- Price
- HMST $11.62
- PGEN $0.78
- Analyst Decision
- HMST Buy
- PGEN Buy
- Analyst Count
- HMST 2
- PGEN 5
- Target Price
- HMST $13.25
- PGEN $7.00
- AVG Volume (30 Days)
- HMST 178.6K
- PGEN 905.3K
- Earning Date
- HMST 01-27-2025
- PGEN 11-14-2024
- Dividend Yield
- HMST N/A
- PGEN N/A
- EPS Growth
- HMST N/A
- PGEN N/A
- EPS
- HMST N/A
- PGEN N/A
- Revenue
- HMST $169,710,000.00
- PGEN $3,963,000.00
- Revenue This Year
- HMST N/A
- PGEN N/A
- Revenue Next Year
- HMST $12.08
- PGEN $426.76
- P/E Ratio
- HMST N/A
- PGEN N/A
- Revenue Growth
- HMST N/A
- PGEN N/A
- 52 Week Low
- HMST $7.21
- PGEN $0.76
- 52 Week High
- HMST $16.10
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- HMST 46.06
- PGEN 39.38
- Support Level
- HMST $11.73
- PGEN $0.76
- Resistance Level
- HMST $12.28
- PGEN $0.97
- Average True Range (ATR)
- HMST 0.49
- PGEN 0.07
- MACD
- HMST 0.15
- PGEN -0.01
- Stochastic Oscillator
- HMST 61.45
- PGEN 7.90
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.